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Surajit Debnath1* and Soma Addya2Abstract
Correlating antifungal Azole drug resistance and mis-sense mutations of ERG11 has been paradoxical in pathogenic
yeast Candida albicans. Amino acid substitutions (single or multiple) are frequent on ERG11, a membrane bound enzyme
of Ergosterol biosynthesis pathway. Presence or absence of mutations can not sufficiently predict susceptibility.
To analyze role of mis-sense mutations on Azole resistance energetically optimized, structurally validated homology
model of wild C.albicans ERG11 using eukaryotic template was generated. A Composite Search Approach is proposed
to identify vital residues for interaction at 3D active site. Structural analysis of catalytic groove, dynamics of substrate
access channels and proximity of Heme prosthetic group characterized ERG11 active site. Several mis-sense
mutations of ERG11 reported in C.albicans clinical isolates were selected through a stringent criterion and modeled.
ERG11 mutants subsequently subjected to a four tier comparative biophysical analysis. This study indicates (i) critical
interactions occur with residues at anterior part of 3D catalytic groove and substitution of these vital residues alters
local geometry causing considerable change in catalytic pocket dimension. (ii) Substitutions of vital residues lead to
confirmed resistance in clinical isolates that may be resultant to changed geometry of catalytic pocket. (iii)These
substitutions also impart significant energetic changes on C.albicans ERG11 and (iv) include detectable dynamic
fluctuations on the mutants. (v)Mis-sense mutations on the vital residues of the active site and at the vicinity of Heme
prosthetic group are less frequent compared to rest of the enzyme. This large scale mutational study can aid to
characterize the mutants in clinical isolates.
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Protein energetics; Protein dynamicsBackground
Candida albicans is an opportunistic fungal pathogen
that causes various mucosal infections (Ge et al. 2010)
in general population and life-threatening systemic in-
fections in immuno compromised patients (Feigal et al.
1991, Richardson & Lass-Florl 2008). The pathogenic
yeast has been exposed to its conventional therapy of
Azole drugs for a considerable period of time due to
longer dosage regime in patients with deranged immun-
ity. This along with it’s over the counter use for topical
applications have lead to Azole resistance, in C.albicans, a
strategy to increase fitness against a constant challenge, a* Correspondence: surajit03@yahoo.co.in
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reproduction in any medium, provided the origsimple evolutionary phenomenon. Azole drugs target 14a-
Lanosterol Demethylase (ERG11), a unique heme-thiolate
enzyme (Pfam: P450, amino acid range 49–520) of the
fungus and competitively inhibits it. ERG11 catalyses two
successive hydroxylations of the 14alpha-methyl group,
followed by its elimination as a Formate moiety, leaving a
14(15) double bond (KEGG) - a key step in biosynthesis of
Ergosterol (Klein et al. 1984). As a vital membrane lipid
Ergosterol provides rigidity, stability, and stress resistance
(Prasad and Kapoor 2004) to the fungal cell and loss of
which leads to cell lysis. Though similar to cholesterol
synthesis in mammals the pathway for Ergosterol biosyn-
thesis differs in some obvious ways (Hitchcock, 1993) and
so ERG11 was targeted for management of this eukaryotic
pathogen in its eukaryotic human host.This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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and high therapeutic index, Azoles have been the drug
of choice for many years as first-line therapy, antifungal
prophylaxis and empirical or preemptive treatment
(Morio et al. 2010). Two classes of Azoles are in use (1)
the Imidazoles in topical infections and (2) Triazoles in
systemic infections (Sanglard et al. 2009). The fungal
pathogen has developed resistance against these antibi-
otics by employing a variety of molecular strategy (Franz
et al. 1998, Sanglard et al. 1998a, 1998b, Sanglard et al.
2003, White 1997a, 1997b, White et al. 2002). Mutations
in the ERG11 gene (leading to reduced affinity of the
enzyme to Azoles) is the most perceived mechanism of re-
sistance (Kelly et al. 1999 a, b, Löffler et al. 1997, Sanglard
et al. 1998a, 1998b, White 1997a, 1997b). However several
issues on the role of ERG11 in Azole resistance has raised:
(i) More than 140 different amino acid substitutions
have been reported in Erg11 of C. albicans clinical iso-
lates (Morio et al. 2010), including multiple substitu-
tions occurring simultaneously in various combinations
(Favre et al. 1999; Goldman et al. 2004). (ii) The genetic
polymorphism suggests that Lanosterol Demethylase is
highly permissive to structural changes. (iii) Evidences
indicate that amino acid changes in ERG11 do not con-
tribute equally to Azole resistance (Morio et al. 2010).
(iv) Several mutations are found in both Azole resistant
and susceptible strains (Chau et al. 2004; Kakeya et al.
2000; Lamb et al. 2000; Loffler et al. 1997; Sanglard
et al. 1998a, 1998b) so the presence or absence of mis-
sense mutation is not sufficient to predict Azole sus-
ceptibility (Morio et al. 2010). (v) Single point mutation
may or may not drastically affect Azole sensitivity of
ERG11 and combinations of point mutations may have
cooperative effects (Sanglard et al. 1998a, 1998b). These
peculiarities of ERG11 mutations in terms of their var-
ied effect make Azole resistance in C.albicans a difficult
problem to address.
Among several examples of discrepancy the single
substituent D116E has been described in Azole-susceptible
as well as Azole-resistant isolates (Chau et al. 2004; Favre
et al. 1999; Marichal et al. 1999; Perea et al. 2001; Sanglard
et al. 1998a, 1998b; White et al. 2002; Xu et al. 2008).
D116E has also been described in combinations in clinical
isolates with quadruplet mutation ERG11_D116E_K128-
T_Y132H_G465S. The mutant has been described in five
reduced susceptibility isolates, but the correlation of this
pattern with resistance is still uncertain (Ying et al. 2013).
Individually occurring A114S (Jiang et al. 2006; Xu et al.
2008) and Y257H (Chau et al. 2004; Xiao et al. 2004; Xu
et al. 2008) single point mutations has been isolated in
different FLZ resistant starins. These missense mutations
also have been reported in combinations, such as
ERG11_A114S_Y257H which was identified in resistant as
well as susceptible dose-dependent isolates (Ying et al.2013). Similarly Y132H has been isolated in resistant
strains (Chau et al. 2004; Favre et al. 1999; Kakeya et al.
2000; Marichal et al. 1999; Sanglard et al. 1998a, 1998b;
Xu et al. 2008) and a cumulative increase in resistance
is reported when it occur with other mutations. G450E
is reported in resistant strains either singly or in various
combinations (Chau et al. 2004; Favre et al. 1999; Goldman
et al. 2004; Loffler et al. 1997, Perea et al. 2001). Combined
occurrence of two substitutions as ERG11_ Y132H _
G450E is reported in resistant strains (Ying et al. 2013).
Some single mutants as K342R that have been isolated only
in Azole susceptible strains (Ying et al. 2013;Goldman
et al. 2004). In contrast some single mutations are
found exclusively in resistant strains, such as P230L
(Li et al. 2004; Xiao et al. 2004) and F380S (Goldman
et al. 2004). There are some substitutions that are
experimentally found to be associated with Azole re-
sistance in C.albicans but have not been recovered in
clinical isolates, such as T315A, Y118A, Y118F, and
Y118T (Baldwin and Kelly 1997; Chen et al. 2007;
Lamb et al. 1997).
In this scenario a large scale analysis of various cat-
egories of ERG11 mutants is required to gain further
insight on the role of the enzyme and its amino acid
substitutions in Azole resistance. Over the years we have
acquired substantial knowledge on amino acid substitu-
tions on ERG11 but the precise way how the amino acid
exchanges influence the drug resistance is not well
explained. With more structural information on the
wild-type and mutated enzymes the intricacy of ERG11
catalysis and effects of mutations will be fully under-
stood. Since ERG11 is a membrane protein which
tends to be resolved poorly by experimental procedure
(X-ray,NMR), molecular modeling may be a reliable
method for structural studies (Shuang et al. 2007).
Earlier studies have attempted ERG11 modeling from
prokaryotic templates. Those were either focused on
fundamental properties (Lewis et al. 1999) of ERG11
or screening of Azoles (Ji et al. 2000, Shuang et al.
2007) and new pharmacophores (Sheng et al. 2006). In
the present work a large-scale structural study of the
ERG11 mutants is undertaken in order to comprehend
the contradiction in terms of occurrence of mutations
with or without Azole resistance in C.albicans.
Results
The wild type ERG 11 of Candida albicans
The wild type ERG 11 of Candida albicans was built using
4K0F.PDB (Lanosterol 14-alpha demethylase of Saccharo-
myces cerevisiae strain YJM789 with intact transmem-
brane domain bound to Itraconazole) resolved at 2.19 Å.
Template was selected by Swiss models customized scor-
ing scheme. Alignment of the target (ERG11 of C.albicans
NCBI Ref Seq: XP_716761.1 of C.albicans, strain SC5314)
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strain YJM789) have 66.21% sequence identity. A pairwise
alignment between the primary structures (in FASTA) by
the Needle program of EMBL revealed a Needle Score of
1815.5. 3D structural difference between a model and its
template is conventionally estimated from RMSD value
which was 0.20 Å among the final ERG11 model and the
template, as estimated by “Iterative Magic Fit” on alpha
carbons of the 3D coordinates. There seems to be consid-
erable homology among the target and the template. The
wildtype ERG11 protein have a predicted molecular weight
of 60675.4 Da and predicted pI is 6.69. The composition of
the wildtype ERG11 protein is tabulated (Table 1).
Structural quality improvement regime for C.albicans
wild type ERG11 given most suitable parameters after
40 cycles of steepest descent and the final model qual-
ity approached the benchmark values of the template.
A detail of the quality improvement regime is given in
the Additional file 1. Total energy of the final model
was −24909.789 K.J/mole (Table 2) which indicates it
to be stable. The catalytic cavity of the final ERG11
can be accessed by two channels and a Heme pros-
thetic group is in close proximity of the catalytic site.
The average Mean Square Displacement 〈R2〉 of each
residue in the Wild type ERG 11 of Candida albicans
is 0.0071 (including highly flexible Trans-membraneTable 1 Amino acid composition of wildtype ERG11
Candida albicans
Amino acids Number of residues Percentage
Ala (A) 25 4.7%
Arg (R) 25 4.7%
Asn (N) 19 3.6%
Asp (D) 32 6.1%
Cys (C) 4 0.8%
Gln (Q) 17 3.2%
Glu (E) 30 5.7%
Gly (G) 32 6.1%
His (H) 13 2.5%
Ile (I) 32 6.1%
Leu (L) 47 8.9%
Lys (K) 35 6.6%
Met (M) 13 2.5%
Phe (F) 33 6.2%
Pro (P) 29 5.5%
Ser (S) 37 7.0%
Thr (T) 32 6.1%
Trp (W) 8 1.5%
Tyr (Y) 29 5.5%
Val (V) 36 6.8%segment) and 0.0051 (Figure 1) (excluding TM). In the
Wild type ERG11 model 305 (57%) out of 536 residues
remains buried in the protein lattice (NetsurfP).
Vital amino acids at the active site of the Wild type ERG
11 of Candida albicans
28 amino acids are predicted to be present on the Wild
type ERG 11 active site while 26 amino acids are pre-
dicted on the template 4K0F by Q-site finder. Highest
number of interactions on any residue are 20 and 12 for
the Wild type ERG 11 and the template respectively
(Figures 2A, 2B).As per the composite approach as-
sumption 8 residues on the Wild type ERG 11 model
and 15 residues on the template are found to be vital for
catalysis (star marked residues, Figures 2A, 2B). Vital
residues identified on Template (Figure 2B) were traced
on the Wild type ERG 11 from the alignment (in FASTA,
Figure 3) between Wild type ERG 11 and 4K0F. The resi-
dues R98 and H405 of the template correspond to K90
and Y401 respectively of the wild ERG of C.albicans. There
are 13 composite residues on Wild type ERG 11 of Can-
dida albicans as seen in the alignment which are vital for
catalysis (Figure 3). K90 was included as vital residue as it
makes 10 interactions in the wild ERG11. Therefore it is
predicted that at least 14 residues are imperative for in-
teractions at the catalytic pocket of ERG11 of Candida
albicans (Figure 4). The surface generated upon these
14 vital residues on the superimposed figure shows the
accommodating surface of the substrate/inhibitor at the
active site (Figure 5) of wild ERG 11 in Candida albi-
cans. Vital residues occur at anterior part of the cata-
lytic furrow. Among the predicted 14 vital residues on
ERG 11 of Candida albicans only two vital residues
P230L and F380S has been found to be substituted in
Azole resistant single mutant Candida albicans (Goldman
et al. 2004, Li et al. 2004; Xiao et al. 2004). Substitution of
Y118 has not been reported but experimentally reported
to cause Azole resistance. Y132 has been reported in com-
bination to other mutants (double and quadruplet substi-
tutions occurring simultaneously).
Heme prosthetic group and the Catalytic cavity of the
Wild type ERG 11 of Candida albicans
Five polar contacts are made with four different amino
acids (Tyr 132, Lys 143, His 468 and Arg 381) with in
2 Å of the Heme. There are 24 amino acids within 4 Å
radius from the prosthetic group (Figure 6). D and A
rings of HEME are in close proximity to the ERG11
active site. Polar contacts are made by O1A, O2A and
O1D, O2D. C and B rings of Heme are distal to the ac-
tive site. TYR118 and TYR132 are present within 4 Å of
the Heme which are predicted to be vital for catalysis.
The catalytic domain is interior (Additional file 1) of the
protein (Wild ERG 11) and its dimensions are 1190 Å3


















633.755 3071.161 2037.510 523.60 −12946.40 −13659.73 −20340.652
Final Model
Wild ERG11
439.711 3200.458 2128.688 657.486 −16825.04 −14511.09 −24909.789
Template
4k0f.pdb
1105.138 2512.448 2736.639 467.556 −14620.22 −13716.33 −21514.770
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Wild type ERG 11 of Candida albicans and the template
also revealed the position of the substrate access chan-
nels (Figure 5). Opening of these access channels at the
entrance of the catalytic furrow are typically flexible as
observed in the Normal Mode Analysis of a low fre-
quency mode (mode 7) (Additional file 1).
Comparative account of wild and the mutant ERG 11 of
Candida albicans
The single mutants of ERG 11 were screened by direct
computational prediction method. A thorough compara-
tive analysis of wild and mutant enzymes were done in
terms of the following: (i) active site geometry (volume
Å3/area Å2 of catalytic groove) and topological alter-
ations at the vital region of active site, (ii) comparison of
local changes at substitution sites in terms of polar con-
tacts (number/bond length), neighboring residues (4 Å
radius) and situation of the Heme (distance in Å from
Cα of wild/substituted residue), (iii) comparison of force-
field energetics (GROMOS96) and (iv) of dynamic proper-
ties (Mean Square Displacement 〈R2〉 of lowest-frequency
normal mode). Wild and mutant models of Candida albi-
cans generated in the study can be acquired from the
corresponding author for academic purpose.
Insight from sequence based computational prediction of
the effect of single amino acid substitutions
Mis-sense mutations occurring singly on ERG 11 of
Candida albicans that are reported to cause AzoleFigure 1 Mean Square Displacement 〈R2〉 of each residue in the Wildresistance (F380S, P230L, Y118A and K342R) were
screened by sequenced based methods. A particular
single amino acid substitution (mis-sense mutation) was
termed ‘Pathogenic’ if all the used classifier predicts it to
be deleterious or disease causing. It is observed that
K342R mutant is completely non-pathogenic as all the
classifier predicts it to be either Neutral or Benign, and it
cause a small alteration on quantitative energy parameter
DDG value (−0.17 Kcal/mol). Rest of the other single
muatnts were significantly ‘Pathogenic’ as all classifier pre-
dicted these mutants either “Deleterious” or “Probably
Damaging” (Table 3).
Observation from four tier comparative biophysical
analysis
The two mutants in which the active site dimensions are
not changed in spite of amino acid substitution are
ERG11_K342R and ERG11_A114S_Y257H, also the mu-
tant ERG11_K342R is significantly more stable than the
wild protein. A minimal change in catalytic pocket dimen-
sion is observed in ERG11_ D116E while a huge increase
in active site dimensions is seen in ERG11_ Y118A. The
mutant ERG11_ P230L showed a decrease in active site
dimensions. In the rest four mutants there was significant
increase of the active site dimension. The quadruplet
mutant ERG11_D116E_K128T_Y132H_G465S highest de-
crease in energetic stability was observed. In the other six
mutants there was reduction in energetic stability. The
details of comparative energetics of the wild type ERG11
and its mutants are given in the Additional file 1. Also atype ERG 11 of Candida albicans.
Figure 2 Active site residues of the Wild type ERG 11 and template 4K0F.pdb showing the number of possible interactions (Q-SiteFinder).
A Active site residues of the Wild type ERG 11 (Amino acid with highest number of interactions (TYR118) and those with a minimum 50% of the
highest interactions are star marked). B Active site residues of the template 4K0F showing the number of possible interactions (Amino acid with
highest number of interactions (TYR126) and those with a minimum 50% of the highest interactions are star marked).
Debnath and Addya SpringerPlus 2014, 3:660 Page 5 of 16
http://www.springerplus.com/content/3/1/660pictorial description of active site dimensions and the
changes brought about at the local environment at mo-
lecular level can be found in the Additional file 1. Consid-
ering the Mean Square Displacement 〈R2〉 of wild ERG11
as reference the R2 plot of the other respective mutants
shows that there has been alteration of 〈R2〉 of the amino
acids at various domains. Minimal fluctuations were re-
corded for the mutants ERG11_ A114S_Y257H and
ERG11_K342R (Additional file 1).
ERG11 phylogeny
For the used dataset LG +G model (Gamma distributed)
of substitution was found to be most suitable with low-
est BIC score of 2258. 252 and AICc score of 1580.854.The final dataset had 68 protein sequences (Figure 7).
The bootstrapped phylogenetic tree (condensed at 50%)
had four distinct clads. While all the fungal and proto-
zoal Cytochromes/ERG11 are in clad A, the higher ani-
mals and the sequences of 3D models (from PDB) are
clustered as a clad B and C respectively. Some highly
diverse sequences are clustered together as clad D.
Discussion
Structural changes in ERG11 are very much likely
(Morio et al. 2010) which is evident from the large num-
ber and variety of mutations. These mutations are
dispersed in hot spots ranging from amino acids 105 to
165, 266 to 287, and 405 to 488 (Marichal et al. 1999).
Figure 3 Alignment of Target (ERG11 of C.albicans) and the template 4K0F showing composite residues that are predicted to be vital
for interactions. SwissModel Sequence Identity 66.21% , Needle Score 1815.5.
Figure 4 Composite residues that are predicted to be vital for various interactions in the active site of C.albicans ERG11.
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Figure 5 Superimposed model of ERG11 of C.albicans over the template 4K0F showing the surface of the 14 composite residues. The
two substrate access channels and the Inhibitor (bound to the template) are seen. Template shown in Helix-sheet-loop and the model of ERG11
of C.albicans is shown in stick formation.
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complete restructuring drive. However, in this study it is
observed that frequency of mutation is significantly low
on the anterior portion of the 3-D catalytic cleft. Ac-
cording to the prediction 14 vital residues are there at
this anterior part of the catalytic cleft (Figure 5) with
highest number of interactions to a ligand. Surprisingly
these residues have the lowest report to have substitutedFigure 6 Amino acid residues within 4 Å from the Heme prosthetic gin clinically isolated mutants of C.albicans. Only three
amino acid residues among the 14 vital residues are
found to be substituted in mutant ERG11 of Candida
albicans (Table 4). All three mutations are associated
with confirmed Azole resistance in clinical isolates. Also
these are mutations that results in most significant alter-
ation of the active site in terms of all the parameters an-
alyzed in this computational study. These mutations areroup of wild type ERG11 of C.albicans.
Table 3 Sequence based prediction of the effect of single amino acid substitutions on ERG11 of Candida albicans
Sl.no Mutant Classifiers
Polyphen Provean I-MUTANT MutPred





1 ERG11_D116E 0.003 (sensitivity: 0.98;
specificity: 0.44)
Benign 0.695 Neutral Neutral −0.47 0.672
ERG11_Y118A 1.000 (sensitivity: 0.00;
specificity: 1.00)
Probably Damaging −9.487 Deleterious Large Decrease in stability −1.83 0.764
2 ERG11_P230L 0.997 (sensitivity: 0.41;
specificity: 0.98)
Probably Damaging −8.773 Deleterious Large Decrease in stability −0.97 0.849
3 ERG_F380L 0.831 (sensitivity: 0.95;
specificity: 0.82)
Probably Damaging −3.075 Deleterious Large Decrease in stability −1.28 0.583
4 ERG11_K342R 0.005 (sensitivity: 0.97;
specificity: 0.74)
Benign −0.443 Neutral Neutral −0.17 0.389
Figure 7 Phylogeny of ERG11. Fungal and protozoal Cytochromes or ERG11 are in clad A, the higher animals and the sequences of 3D models
(from PDB) are clustered as a clad B and C respectively. Clad D is highly diverse sequences.
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Table 4 Selected mutations on Candida albicans ERG11 and their features
Sl.no Mutant Substitution
type






1 ERG11_A114S _Y257H Double
mutant
Xu et al. 2008; Ge et al. 2010;
Ying et al. 2013
Detected in clinical isolates. Described
in Azole resistant as well as susceptible
isolates. Also described as single





Chau et al. 2004; Favre et al. 1999;
Marichal et al. 1999; Perea et al. 2001;
Sanglard et al. 1998a, 1998b;
White et al. 2002
Detected in clinical isolates. Described
in Azole-susceptible and Azole-resistant







Ying et al. 2013 Detected in clinical isolates. Detected
in Azole resistant strains. Several




Chen et al. 2007; Lamb et al. 1997. The mutation have been clearly
associated with resistance by
experimental methods but have not




Chau et al. 2004; Favre et al. 1999;
Goldman et al. 2004; Loffler et al. 1997,
Perea et al. 2001
Detected in clinical isolates. Detected




Li et al. 2004; Xiao et al. 2004 Detected in clinical isolates. Detected










Goldman et al. 2004, Ying et al. 2013 Detected in clinical isolates. Described
only in Azole-susceptible isolate.
None None
Mutants from N terminal end of ERG11.
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of studies that reports their occurrence. Substitution of
Y118 has been predicted to be associated with resistance
by in-vitro studies (Chen et al. 2007; Lamb et al. 1997)
but has never been recovered in clinical isolates. Similar
is the case with the amino acids in the proximity (within
4 Å) of the Heme prosthetic group. Among 24 amino
acid residue around the Heme only six amino acids
have been found to be substituted in clinical isolates of
Candida albicans (Additional file 1). All the mutants
are exclusively Azole resistant and some are reported to
increase Azole MIC by several folds. Mutations in T315
and Y118 have been clearly associated with resistance
but not yet detected in clinical isolates (Chen et al.
2007; Lamb et al. 1997). Therefore the observations
indicate that a substitution on a vital residue or on a
residue close to Heme prosthetic group is less likely to
occur. And if at all it occurs will confer strong Azole
resistance.
In this study single mutations occurring on three types
of residues; predicted vital residues, active site residues
and non active site residues were included. Initial screening
of sequence based computational methods was consistent
in sorting the mutants (Table 3) in various categoriesof severity. ERG11_Y118A was the most “Pathogenic”
followed by ERG11_ F380S and ERG11_ P230L. The mu-
tant ERG11_ D116E was intermediate in terms of patho-
genecity and ERG11_K342R was completely neutral. The
geometry of the catalytic pocket was found to be signifi-
cantly altered in the mutants ERG11_ Y118A, ERG11_
F380S and ERG11_ P230L. An increase in volume and area
of the catalytic pocket in ERG11_ Y118A and ERG11_
F380S may lead to decreased affinity of Azole. Similarly a
decrease in volume and area (in ERG11_ P230L) may lead
to inaccessibility of catalytic site and subsequent resistance.
This may explain exclusive Azole resistance in the clinical
isolates of ERG11_ F380S and ERG11_ P230L. Clinical
isolates of ERG11_Y118A are not reported and this indi-
cates the functional significance of the residue Y118. Geo-
metrical changes at the catalytic pocket in the mutants
may have occurred due to significant changes in the local
environment, for example in ERG11_Y118A, polar con-
tacts with neibouring vital residues were demolished and
the distance of prosthetic group from the mutation site in-
creased. Similarly in ERG11_ F380S vital residues from
the vicinity were missing and an increase in polar distance
among vital residues may have resulted in geometrical dis-
tortion of active site. In ERG11_P230L, there has been a
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portant in functional folds of an active site (Charbonnier
et al. 1999) as Proline has been substituted. A Proline sub-
stitution may change the immediate chemical surrounding
of a nucleophile by making it more hydrophilic (Roos
et al. 2007). The specific conformation of Proline imposes
ma-ny restrictions on the structural aspects of peptides
and proteins conferring particular biological properties
(Cunningham and O’Connor, 1997). The alteration of
geometry due to the vital residue substitutions in the
mutants by means of surface generation is shown in the
Additional file 1. In ERG11_D116E and ERG11_K342R
there is either minimal or no change in the active site
geometry. Since ERG11_K342R is a distant residue
therefore the local changes taken place in the mutant
have not influenced the active site. The minimal change
on active site in ERG11_D116E can be attributed to the
the substitution of a hydrophilic and negatively charged
residue by another similar amino acid, however Glutamate
is slightly bigger than Aspartate. It is also observed that
the Energy scores (GROMOS97) of the mutants can indi-
cate the consequences of the mutations. Among the single
mutations F380L is the most destabilizing followed by
Y118A and P230L. On the other hand K342R mutation is
highly stabilizing which shows minimum fluctuations in
the Normal Mode Analysis. The mutant ERG11_D116E
is intermediate in terms of energy scores. Among the
clinical isolates harboring single mutations, consider-
able diversity in resistant phenotype is observed. For
example ERG11_K342R is isolated exclusively from sus-
ceptible strains while ERG11_D116E was isolated from
resistant as well as susceptible C.albicans. From the ana-
lysis of single mutants it is assumed that vitality of an
amino acid for possible interactions with a ligand at the
active site is an important factor that determines severity
of active site alteration on the occurrence of a mutation
leading to Azole resistance in Candida albicans.
Three mutants in which multiple mutations coexist on
the ERG11 were analyzed. In the mutant ERG11_A114-
S_Y257H, none of the substituted residues were vital
residues or active site residues. The mutations did not
alter any local parameters and had no effect on the ac-
tive site geometry, which explains its occurrence in sus-
ceptible isolates. But interestingly the mutant is also
isolated from Azole resistant strains as well. A possible
explanation for occurrence of this double mutant in sus-
ceptible as well as resistant clinical isolates may be har-
boring of other unrelated mutations (such as on the
efflux pump proteins) in the strain that results in resist-
ant phenotype. It may be noted that occurrence of mul-
tiple mutations in ERG11 may not ensure alteration in
catalytic pocket leading to confirmed resistance in clinical
isolates. In the double mutant ERG11_Y132H_G450E sig-
nificant alteration of the local environment has lead tosevere alteration of the active site. This may explain its oc-
currence on only resistant strains and also indicate that the
vitality of Y132 is indispensable for ERG11 geometry. The
double mutations Y132H, G450E on the ERG11 is also con-
siderably more destabilizing then the double mutations
A114S, Y257H. Dynamic changes on the mutants as ex-
plained by Normal Mode Analysis also indicate significantly
more alteration in ERG11_Y132H_G450E than that of the
ERG11_A114S_Y257H. The quadruplet mutant ERG11_
D116E_K128T_Y132H_G465S has been isolated in fungus
with reduced susceptibility to Azole. Single mutant with
D116E resulted in minimal alteration of active site and
another double mutant with Y132H resulted in significant
change. In this quadruplet mutant alteration of active site is
more than the both of the single or double mutant. This
mutant structure is also most unstable in energetic terms
and posse’s significant fluctuation of its molecular motions.Conclusion
It is apparent that significant geometrical changes in the
ERG11 active site domain will take place if the amino
acids responsible for key molecular interactions (with its
substrate or inhibitors) are substituted. An increase or de-
crease in the catalytic pocket dimension is most likely to
bring about Azole resistance. Several parameters of the
local environment determine the severity of the change in
active site dimension. This study identifies the vital resi-
dues, mutations of which will cause confirmed Azole re-
sistance. If a mutation is far from the active site or the
Heme group it may not cause Azole resistance. Moreover,
Azole resistance in Candida albicans may be a multifac-
torial process (Balkis et al. 2002) that can be mediated
through multiple underlying mechanisms independent of
ERG11. Resistance can be acquired through (i) transcrip-
tional activation leading to over expression of the genes
encoding at least two groups of efflux pumps either be-
longing to ABC (the ATP-binding cassette that include
CDR1, CDR2 etc.) or MFS (major facilitator include
MDR1) super-families of proteins (White 1997a, 1997b;
Maebashi et al. 2002). This results in reduced intracellular
accumulation of drugs.(ii) Altering the synthetic pathway
of fungal sterols by-passing ERG11 (Claire et al. 2010) is
also reported as a mechanism of resistance. (iii) The fungus
may even induce chromosomal aneuploidy (Perepnikhatka
et al. 1999; Selmecki et al. 2009) as chromosome 5 duplica-
tion or the presence of a chr5L isochromosome to acquire
resistance. It is also important to note that, several of these
mechanisms are often found to be combined in clinical
isolates (Cernicka and Subik, 2006; Chau et al. 2004;
Coste et al. 2007; Franz et al. 1998; Goldman et al.
2004). Therefore in order to device a full proof strategy
to combat Azole resistance functional genomics has to
explore all possible drug targets.
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that posses maximum interaction with substrate or in-
hibitor at the ERG11 active site have highest propensity
to cause confirmed resistance by geometrical change of
the catalytic pocket. Intra residue local interaction
among amino acids of the catalytic site may be a deter-
mining factor if it involves one or more vital residues.
But if the substituted residue is far from the anterior
part of the ERG11 active site or at a distant location
from Heme group, it may not determine Azole resist-
ance by geometrical change of the active site. However,
since a large amount of mutations are yet to be ex-
plained for their Azole resistance it is argued that other
underlying mechanisms (as reviewed by Prasad and
Kapoor 2004) may be involved. For effective therapeutic
intervention against resistant C.albicans in T.B or AIDS
patients novel drug targets may be prioritized. The mu-
tant models used in the study may be used for further
insight of Azole binding in the active site or to analyze
potential interaction with the Heme prosthetic group via
methods like Quantom Mechanics-Polarized Ligand
Docking (QPLD). This computational study may be con-
sidered a dry-run prior to the wet-lab experimentations
that involve significant investment in various terms. The
in-silico strategy to identify vital residues on C.albicans
ERG11 can substantially speed up experimental work
and reduce associated costs towards characterization of
mutations.
Materials and method
In this study the objective is to evaluate (i) how Azole re-
sistance in C.albicans can be accounted for structural
changes in the ERG11 active site. The paper evaluated (ii)
the role of local environment (polar bonds, proximal resi-
dues and Heme prosthetic group) around amino acid sub-
stitutions. Analysis of mutation induced alterations in (iii)
energetic stability in 3D models and (iv) dynamic changes
(by normal Mode Analysis) were done. ERG11 phylogeny
analysis will throw light on its variability among several
taxa.
Primary sequence of Candida albicans ERG11
Uniprot, a global database was queried for Lanosterol 14-
alpha-Demethylase (ERG11) in Candida albicans. A
reviewed entry for ERG11 in C.albicans, the NCBI Refer-
ence Sequence: XP_716761.1 of C.albicans, strain SC5314
was selected for the study. The primary sequence is down-
loaded in FASTA format and used as the wild type ERG11
sequence. Composition of amino acids in ERG11 and its
physicochemical parameters were computed (Protparam).
Homology Modeling of Candida albicans ERG11
Out of several million protein sequences, less than 0.1
million have their structures determined experimentallyby X-ray or NMR. However, increased reliability of
alignment algorithms and modeling programs paved a
way to predict 3D coordinates of proteins for which we
only have knowledge of the primary sequence sharing
certain homology with that of experimentally deter-
mined proteins.
Swiss-model (Kiefer et al. 2009) is a user friendly and
computationally economic method that generates several
perspective models of the query and ranks them based
on a scoring scheme customized in the algorithm. It uses
various templates and analyses them in terms of QMEAN
Z-Score. The higher is the score; the better is the model
quality. It also describes the modeled residue range, the
template information with its resolution, percentage of se-
quence identity as well as a E-value. According to the need
the user can also specify a PDB template by its code or
can upload a PDB file to be used as a template. Most im-
portantly, a predicted structure from the algorithm ac-
commodates the co-ligands or metal atoms, presence of
which (co-ligands and metal ions) may determine struc-
tural or functional integrity of the protein.
Energetic refinement and geometrical validation of models
The overall stereochemical quality of the protein models
were assessed and Molprobity (Chen et al. 2009) pro-
vides broad spectrum solidly based evaluation of model
quality at both global and local levels. It utilizes the
power and sensitivity provided by optimized hydrogen
placement and all-atom contact analysis, complemented
by updated versions of covalent geometry and torsion
angle criteria. Molprobity generates all atoms Clashscore
which is the number of serious steric overlaps (>0.4 Å)
per 1000 atoms. The classical Ramachandran plot ana-
lysis is done in-terms of the number and percentage of
Ramachandran outliers and Ramachandran favored resi-
dues. The Molprobity score, is a protein geometry param-
eter that is dependent upon the Ramachandran outliers
and favored residue percentage. It also gives the number
and percentage of Poor roamers, Cβ deviations >0.25 Å,
Bad backbone bonds and angles.
Stereochemical quality of reconstructed protein models
are conventionally enhanced by energy minimization pro-
tocols. This improves the physical realism and structural
accuracy of protein models. Accuracy in protein structure
is improved by repairing distorted geometries if any, for
example by removing steric clashes (Chou and Carlacci,
1991) and by curtailing the free energy to make the pro-
tein stable. SwissPDB-Viewer, SPdbV (Guex, and Peitsch,
1997) minimizes energy of 3D structures implementing
GROMOS96 forcefield and the computations are done
in vacuum devoid of a reaction field. User can optimize
the steps of conjugate gradient or steepest descent
methodologies. The software returns energy scores in
terms of bond, non-bond, angles, torsion, improper and
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program the energy optimization cycles to stop when
ΔE between two subsequent steps or even the force act-
ing on any atom of the 3D model is below a threshold.
The user can either use a harmonic constraint or can
lock on selected residues for energy optimization.Optimization of model quality
Homology modeling although uses an experimentally
determined PDB template, the resultant model may not
achieve finer structural quality. The optimization protocol
assumes that the values of quality assessment parameters
of a good homology model should approach towards simi-
lar assessment values of the template (experimentally de-
termined 3D co-ordinates). For this the model as well as
the template (used for homology modeling) are analyzed
by Molprobity in terms of Clashscore, Poor rotamers,
Ramachandran outliers and favored, MolProbity score,
Cβ deviations, Bad backbone bonds and angles. Mol-
probity parameters of the template were considered as
the benchmark value of protein quality for a respective
model. Energy minimization of the models by executing
GROMOS96 force field method was done in steps of
20 cycles of Steepest descent and/or Conjugate gradi-
ent. After every step of 20 cycles the quality was again
assessed by Molprobity. Cycles of minimization were
carried out until the quality approaches the benchmark
values of the template. If quality of model deteriorates,
minimization steps were stopped. Candida albicans
ERG 11 Model with best quality parameters was se-
lected for further analysis.Analysis of active site characteristics of Candida albicans
ERG 11: Identification of vital residues in the active site
by composite approach
It is assumed that higher the number of atomic interac-
tions upon an amino acid residue, higher is its probabil-
ity to be imperative in the active site chemistry. Vital
amino acids in the 3D active site of Candida albicans
ERG 11 were identified by a composite approach via
Q-SiteFinder (Laurie and Jackson 2005) of the Leeds
University server. It uses the van der Waals interaction
of a methyl probe and an interaction energy threshold
to determine favorable binding clefts and not solely de-
pend on geometrical criteria for prediction. The output
lists all the potential atomic interactions incurred by
the amino acids. Thus multiple interactions upon a
single amino acid residue are predicted. Since this
application probes site binding energies with the ap-
propriate energy cut-off rather than purely geometric
criteria to determine favorable binding sites on pro-
teins, it efficiently reduces the tendency to increase
predicted site volumes with protein size.The composite approach for predicting vital active site
residues in Candida albicans ERG 11 followed these
steps: (i) initially all the active site residues were pre-
dicted from optimized and validated homology model of
Candida albicans ERG 11 as well as from the PDB tem-
plate (experimentally determined 3D protein structure
from RCSB PDB database). (ii) Predicted active site resi-
dues with the number of atomic interactions upon each
of the amino acids (both for model and template) were
noted. (iii) From each protein (model and template) the
amino acid with highest number of interactions and
amino acids with interactions at least half of that highest
number were identified. These amino acids are assumed
to be the most potential candidates for ligand binding at
the active site. (iv) Primary sequences of the Candida
albicans ERG11 homology model and its template (in
FASTA format) were aligned by the Needle program of
EMBL. (v) Mapped of the potential active site residues
of the template were done upon the Candida albicans
ERG 11 homology model from the alignment. Finally (vi)
the Vital active site residues of Candida albicans ERG 11
were assigned by compositing predictions of potential
amino acids for the model as well as the template.
The template which is an experimentally determined
crystal structure of a protein may have an already bound
substrate or inhibitor co-crystallized at the catalytic cleft.
The bound ligand may increase probable prediction of
vital residues. Therefore, in the composite search ap-
proach for vital residues the template along with the
homology model was used. So the definition of Vital
amino acid residues on the active site of Candida albi-
cans ERG 11 stands as: the active site amino acids with
maximum propensity for interaction. The composite ap-
proach for detection of vital amino acids at the Candida
albicans ERG 11 active site was found to be effective as
evident from the results.
Analysis of active site geometry of Candida albicans ERG
11: The Substrate access channels, their dynamics and the
Heme moiety
In order to visualize the catalytic domain of Candida
albicans ERG 11 the optimized and validated homology
model is superimposed on to the template structure in
Pymol (DeLano 2002). The template was visualized in its
secondary structure (helix-sheet-loop) and the Candida
albicans ERG 11 homology model was visualized with
each amino acid in its native conformation (stick). The
surface of the residues was generated that were pre-
dicted to be the vital residues at active site as per the
composite approach. The template structure has a
bound ligand on its active site, and the superimposition
with surface generation of vital active site residues
clearly showed the location of the access channels and
the active site cavity. This visualization indicated that
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at the active site is a suitable method.
Cavities in proteins may generally be related with the
dynamics and function of a protein since it accommodates
a substrate. Thermodynamic and mechanical properties of
catalytic proteins which accommodate a substrate in its
interior may be such that the channel gates of its catalytic
cleft will vibrate in a Normal mode. Normal mode analysis
characterizes the collective motions of a group of atoms
which is based on the harmonic approximation of the
potential energy function around a minimum energy
conformation (Suhre and Sanejouand, 2004). Therefore,
normal mode calculations provide an alternative to
molecular dynamic simulations for studying collective
motions in macromolecules (Shahila et al. 2003). Ana-
lysis of Mean Square Displacement 〈R2〉 of the lowest-
frequency normal mode to study the dynamic behavior
of Candida albicans ERG 11 homology model was
done (ElNe’mo, Suhre and Sanejouand, 2004).
The mechanically flexible substrate access channels
lead to a catalytic cavity and its volume and area deter-
mines its substrate or inhibitor binding propensity. Ana-
lysis of the dimensions of the Candida albicans ERG 11
catalytic pocket in terms of volume (Å3) and area (Å2)
was done. Local environment of the Heme prosthetic
group was analyzed in terms of polar contacts and iden-
tification of the neighboring residues within a 4 Å radius
around the Heme.
Missense mutations on ERG 11 of azole resistant Candida
albicans
Review of literature indicated that missense mutations
on ERG 11 of Candida albicans may either occur singly
or in combination. The dataset of mutant ERG 11 of
Candida albicans for this study focused on the follow-
ing: (i) mutants with single and multiple amino acid sub-
stitution/s (ii) single mutants with substitution on a
predicted vital residues and non-vital residues, (iii) mul-
tiple mutants with substitution of at least one predicted
vital amino acid residue (with concurrent substitution/s
of non vital or active site residue/s), (iv) single and mul-
tiple mutants with substitutions only on non vital resi-
due/s. Mutants were (Table 4) identified from literature
followed by the prediction of vital active site residues of
ERG 11 in Candida albicans by means of the composite
approach (results section).
Modeling the mutant ERG 11 proteins of Candida albicans
The optimized and validated homology model of wild
type Candida albicans ERG 11 was used for modeling
the mutant ERG 11 of Azole resistant Candida albicans
by site specific substitution. Wild type amino acids were
substituted by the mutant residues for the single, double
and quadruplet amino acids. For every substitutionSPdbV generates several conformations. The conform-
ation with highest energetic stability was selected for
each substitution. This ensures uniformity in terms of
energetics during the amino acid substitutions. All the
mutant models were further optimized and validated fol-
lowing the method explained for optimization and valid-
ation of the wild ERG11 model.Direct sequence based computational prediction of the
effect of single amino acid substitutions
Computational analysis to study role of a mutation may
be used for screening purpose prior to a computationally
expensive study.Evolutionary trend based analysis
Polymorphism Phenotyping (PolyPhen, Adzhubei et al.
2010) and Provean (Choi 2012) are evolutionary trend
based classifier of amino acid substitutions. PolyPhen
utilizes a combination of sequence and structure-based
attributes for the description of an amino acid substitu-
tion, and the effect of mutation is predicted by a native
Bayesian classifier. Provean runs a Blast search and the
clustering of BLAST hits is performed by CD-HIT with
a parameter of 75% global sequence identity. The top 30
clusters of closely related sequences form the supporting
sequence set are used to generate the prediction.Analysis based on free energy change
Amino acid substitutions leading to alteration of stability in
Candida albicans ERG 11 were predicted via a neural-
network-based application. The tool (I-Mutant) was trained
on a data set derived from ProTherm (Bava et al. 2004), a
comprehensive database of protein mutations.Molecular effect based prediction
Mutations effect protein functions at molecular level and
an algorithm (MutPred, Li et al. 2009) trained using the
deleterious mutations from the Human Gene Mutation
Database (Stenson et al. 2009) and neutral polymorphisms
from Swiss-Prot (Boeckmann et al. 2003) efficiently classi-
fies them in Candida albicans ERG 11.Biophysical analysis of Candida albicans ERG 11 and its
mutants
Amino acid substitution in a catalytic protein may alter
several of its characteristic properties leading to alter-
ation in its 3D active site. In this section several bio-
physical parameters for a comparative account among
the wild and mutant Candida albicans ERG 11 were
considered.
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ERG 11 and its mutants
The volume and the area of the catalytic cleft are import-
ant factor as this accommodates a substrate or a substrate
inhibitor. Analysis of the volume (Å3) and the area (Å2) of
the ERG 11 active site in the wild type and the mutant pro-
teins was done. Cavity detection algorithm (SPdbV) identi-
fies potential cavities on a protein and returns the volume
and area. The geometrical parameters were noted for each
model and compared with the wild type parameters.
Comparative analysis of local environmental changes at
the amino acid substitution sites in the Candida albicans
ERG 11 and its mutants
Influence of an amino acid on its local environment can
be analyzed in terms of its interaction with other residues.
Substitution of the amino acid may or may not alter the
interactions of the wild type residue in the polypeptide
chain. This in turn may influence structure and function.
Number of polar interactions and the bond lengths are
measured in the wild type and mutant ERG 11 at the wild
and substituted amino acids (Pymol). The neighboring
residues were identified at wild and substituted sites with
in a 4 Å radius from the Cα of the amino acids.
The distance of the Heme prosthetic group (in Å) was
determined from the wild and mutant residues in the
proteins. This analysis may indicate the influence of the
missense mutations locally on the protein phenotype.
Local environment of the mutant in comparison to the
wild residue on the basis of amino acid characteristic
were also analysed (HOPE, Venselaar et al. 2010).
Comparison of forcefield energetics of Candida albicans
ERG 11 and its mutants
Molecular mechanics or force field methods use classical
type models to predict the energy of the molecule as a
function of its conformation. This allows prediction of
equilibrium geometries, transition states and relative ener-
gies between conformers or between different molecules.
The total energy is expressed as a sum of Taylor series ex-
pansions for the stretches for every pair of bonded atoms,
and adds additional potential energy terms contributed by
bending, torsional energy, van der Walls energy, and elec-
trostatics (Leach, 2001). Energy scores in terms of bond,
non-bond, angles, torsion, improper,electrostatic energies
and the total energy of the models in Kilo Jules/mole were
estimated (GROMOS96). The reference energy values of
wild Candida albicans ERG 11 was compared with energy
values of the mutants.
Comparison of dynamic properties of Candida albicans
ERG 11 and its mutants
Mean Square Displacement 〈R2〉 was calculated for all
protein models of ERG 11. The R2 values of wildtypeprotein are the reference against which mutant values
are comparatively plotted. A straight line in the plot for
a protein will indicate complete identity of molecular
motion with the reference protein, wild ERG11. The
comparative analysis may indicate dynamic changes
brought about by the mis-sense mutations.
Phylogenetic analysis of ERG11
Protein sequences (FASTA) from GenBank were retrieved.
Out of 421 entries the hypothetical proteins, duplicate en-
tries, un-named proteins and vitamin D hydroxylases were
removed. Selected protein sequences were aligned by
ClustalW (Blosum Protein Weight Matrix) and several
duplicate entries were removed by default. Most suitable
substitution model was identified using maximum likeli-
hood statistical method with complete deletion and very
strong branch swap filter (MEGA 6, Tamura et al. 2013).
Phylogeny reconstruction was done using the identified
substitution model and Maximum Likelihood (ML) statis-
tical method with Nearest-Neighbor-Interchange (NNI)
heuristic method. Gaps or missing data were completely
deleted to increase robustness. Bootstrap test of phylogeny
was done with 500 replications. The final tree was con-
densed at 50% cut-off value.
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